Skip to main content
SP5007,785.76-0.17%DOW53,732.41-0.20%NASDAQ26,729.16-0.28%BTC$62,945.00-0.85%ETH$1,880.32-0.35%GOLD$4,432.00+0.26%OIL$82.40+1.42%
Smart Investors Daily
Sign InSign Up Free
RA

NASDAQ · RAPT

RAPT Therapeutics, Inc. Common Stock

Healthcare · Biotechnology

$58.01

Up+$0.00 (+0.00%)

Updated Aug 16, 2026, 8:04 AM

SID Score

4.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
584.43M
P/E ratio
-9.02
Dividend yield
0.00%
52-week range
— – —
Volume
10.85M
Avg. volume
476.79K

Price performance

RAPT price history

1M range · 0 trading sessions · Daily adjusted prices

RAPT does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest RAPT news

The latest Smart Investors Daily articles mentioning RAPT.

Stock researchCompany · Overview

RAPT research

Overview

Company profile and research snapshot.

Company profile

RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$49.17
Implied upside
—
Analysts
—
RAPT recent ratings
DateFirmRatingTarget
Jan 21, 2026BarclaysEqual-Weight—
Jan 21, 2026Leerink PartnersMarket Perform—
Jan 20, 2026Wells FargoEqual-Weight—
Jan 20, 2026HC Wainwright & Co.Neutral—
Jan 20, 2026TD CowenHold—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Mar 1, 2026

Assessing RAPT Therapeutics (RAPT) Valuation After A Sharp 3 Month Share Price Surge

Recent performance snapshot for RAPT Therapeutics (RAPT) RAPT Therapeutics (RAPT) has drawn investor attention after a sharp past 3 months move, with the stock showing a total return of 84.01% and a last close of US$57.98. See our latest analysis for RAPT Therapeutics. The recent 84.01% 3 month share price return has come after a quieter short term move, and sits alongside a very large 1 year total shareholder return, although the 3 and 5 year total shareholder returns remain weak. If RAPT...

Yahoo · Feb 25, 2026

GSK to buy Canada's 35Pharma for $950 million

Feb 25 (Reuters) - GSK on Wednesday agreed to pay $950 million in cash for Canadian biopharmaceutical company 35Pharma Inc, which is developing a medicine for pulmonary hypertension.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By